Andrew Polovin Sells 2,951 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 2,951 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the sale, the executive vice president directly owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total transaction of $443,912.00.
• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28.

Tempus AI Price Performance

TEM traded down $2.52 during trading on Friday, reaching $77.84. The stock had a trading volume of 9,310,212 shares, compared to its average volume of 7,226,184. The stock has a 50 day moving average of $57.19 and a two-hundred day moving average of $52.90. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The firm has a market capitalization of $14.04 billion, a price-to-earnings ratio of -54.06 and a beta of 3.72. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the firm earned ($0.22) EPS. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, equities analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the period. Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the period. Geode Capital Management LLC lifted its position in shares of Tempus AI by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock valued at $110,478,000 after acquiring an additional 141,680 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Tempus AI by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock valued at $109,938,000 after acquiring an additional 405,662 shares in the last quarter. Finally, Lingotto Investment Management LLP boosted its stake in Tempus AI by 45.9% in the 4th quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock worth $67,525,000 after purchasing an additional 359,667 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Analysts Set New Price Targets

A number of brokerages have weighed in on TEM. Roth Capital started coverage on shares of Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. BTIG Research increased their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Raymond James Financial set a $80.00 target price on shares of Tempus AI in a report on Wednesday, September 2nd. Finally, Lake Street Capital cut Tempus AI to a “hold” rating in a report on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $69.33.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.